Ciarleglio Anita E, Ma Carolyn
Assistant Specialist, University of Hawai'i at Hilo, Daniel K. Inouye College of Pharmacy, Hilo, HI.
Dr. Ma is a Board Certified Oncology Pharmacy Specialist with experiences in health systems administration and pharmacy academe.
Hawaii J Med Public Health. 2017 Sep;76(9):265-269.
The precision medicine initiative brought forth by President Barack Obama in 2015 is an important step on the journey to truly personalized medicine. A broad knowledge and understanding of the implications of the pharmacogenomic literature will be critical to the achievement of this goal. While a great amount of data has been published in the areas of pharmacogenomics and pharmacogenetics, there are still relatively few instances in which the need for clinical intervention can be stated without doubt, and which are widely accepted and practiced by the medical community. As our knowledge base rapidly expands, issues such as insurance reimbursement for genetic testing and education of the health care workforce will be paramount to achieving the goal of precision medicine for all patients.
巴拉克·奥巴马总统于2015年提出的精准医疗计划是迈向真正个性化医疗征程中的重要一步。对药物基因组学文献的广泛了解和认识对于实现这一目标至关重要。虽然在药物基因组学和药物遗传学领域已经发表了大量数据，但仍有相对较少的情况能够毫无疑问地表明临床干预的必要性，并且被医学界广泛接受和实践。随着我们的知识库迅速扩展，基因检测的保险报销以及医疗保健人员的教育等问题对于实现所有患者的精准医疗目标至关重要。
